Background: Genomic studies have revealed that multiple genes are mutated at varying frequency in endometrial cancer (EC); however, the relevance of many of these mutations is poorly understood. An EC-specific recurrent mutation in the MAX transcription factor p.His28Arg was recently discovered. We sought to assess the functional consequences of this hotspot mutation and determine its association with cancer-relevant phenotypes. Methods: MAX was sequenced in 509 endometrioid ECs, and associations between mutation status and clinicopathologic features were assessed. EC cell lines stably expressing MAX H28R were established and used for functional experiments. DNA
Endometrial cancer (EC) is the most common gynecologic cancer in the United States and one of a few cancer types for which both incidence and mortality are increasing (1, 2) . Endometrioid endometrial cancer (EEC) is the most common histologic subtype, accounting for approximately 85% of cases (3) . Genetically, EEC is a highly mutated tumor type. Many driver mutations have been identified; however, our present understanding of gene defects that contribute to specific cancer processes such as invasion, metastasis, and angiogenesis is limited. Based on recent findings from The Cancer Genome Atlas (TCGA) and subsequent in silico analyses, the transcription factor MYC-associated factor X (MAX) emerged as a new genetic factor likely to influence EC tumor biology (4) (5) (6) .
MAX is the obligate binding partner of MYC, a master transcription factor with pro-proliferation, pro-growth, and oncogenic functions. MYC has low binding affinity for DNA, but MYC:MAX heterodimers bind E-box sequences to regulate gene expression (7, 8) . MAX plays an equally important role as a binding partner for members of the MAX dimerization proteins (MXDs) family including MNT, MXD1,3-4, and MGA. MAX:MXD family dimers oppose the pro-growth effects of MYC by promoting expression of differentiation and quiescence genes (9) (10) (11) .
Deregulation of MYC family members is seen in a variety of tumors (12) . MAX abnormalities, however, are rare, with the notable exceptions of loss-of-function germline and somatic variants in pheochromocytoma and paraganglioma patients, and somatic loss-of-function mutations in small cell lung cancer (13) (14) (15) . The missense MAX mutations reported by TCGA in ECs stand in sharp contrast to these loss-of-function MAX variants (4) . One particular hotspot mutation discovered by TCGA, the MAX p.His28Arg mutation, has not been previously reported in primary specimens from other cancer types to date. We undertook studies to investigate MAX's role in EC, particularly the functional consequences of the p.His28Arg mutation.
Methods

Patient Materials
Uterine cancer samples were collected by the Division of Gynecologic Oncology, Washington University, St. Louis, from 1991 to 2010. Written informed consent for this study was obtained and approved by Washington University protocols HSC 91-0507 and HSC 93-0828 and Ohio State University protocol 2012C0116. Microsatellite instability (MSI) status and POLE mutation testing were performed previously (16) (17) (18) . Nonendometrioid and POLE-mutated ECs were excluded.
Targeted Sequencing
All coding exons in MAX long and short isoforms (NM002382 and NM145112, respectively) were sequenced to an average of 170Â in 509 EECs using the TruSeq Custom Amplicon Kit v1.5 and a MiSeq instrument with Reagent Kit v2 (Illumina, San Diego, CA). Variants were identified using Miseq Reporter software (v2.5.1) (19, 20) .
Electrophoretic Mobility Shift Assays
Oligonucleotide sequences used in electrophoretic mobility shift assays (EMSAs) are given in Supplementary Supernatants were aliquoted and snap frozen on dry ice. Cells were counted to normalize VEGFA protein quantification. VEGFA levels were measured using the Human VEGF EnzymeLinked Immunosorbent Assay (ELISA) Kit (ThermoFisher Scientific). Absorbance at 450 nm was measured, and a fourparameter logistic standard curve was used to determine concentrations. Biologic duplicates were assayed in technical duplicate.
Microfluidic Sprouting Assay
Microfluidic HUVEC sprouting assays were performed as described previously (21) . Conditioned media from MAX WT , MAX H28R , or empty vector (EV) AN3CA cells was introduced into HUVEC-lined microchannels, and HUVEC sprouting into a central collagen channel was observed. Images of HUVEC sprouting were acquired immediately before and 24 hours after treatment with conditioned medium. Images were processed and analyzed with ImageJ software to calculate the normalized sprouting ratio for each aperture. Additional details are provided in the Supplementary Methods (available online).
In Vivo Tumor Models
Six-to eight-week-old outbred, NCr-nu/nu females were utilized for flank (six to 11 mice per group) and intraperitoneal (two to three mice per group) xenograft studies. 
Immunohistochemistry and Xenograft Vessel Quantification
Immunohistochemistry was performed using a Bond Rx autostainer (Leica, Wetzlar, Germany 
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were captured using the Vectra Intelligent Slide Analysis System (PerkinElmer, Waltham, MA). Quantification of vessel area was performed on MECA-32 stained slides for six random 20Â images per xenograft using inform 2.1 (PerkinElmer) and imageJ. Additional information on sample preparation is provided in the Supplementary Methods (available online).
Statistical Analysis
Associations between MAX mutation status and MSI, stage, recurrence/progression, age, lymphovascular space invasion, race, and adjuvant therapy were calculated using two-sided Fisher's exact tests. P values for body mass index (BMI) and grade were calculated using two-sided chi-square tests. For univariate survival analysis, P value was determined by log-rank test, and hazard ratio (HR) and 95% confidence interval (CI) were obtained using the Mantel Haenszel approach. Cox proportional hazards multivariable analysis was performed using MAX mutation status and features known to be associated with outcome (18, 22) . The proportional hazards assumption was tested using the scaled Schoenfeld residuals and the Kaplan-Meier transformed survival times. None of the variables in the multivariable analysis was statistically significant (P> .05), indicating a lack of evidence for departure from the proportional hazards assumption. Ten patients with perioperative deaths (<30 days) and 24 with persistent (stage IVB) disease were excluded from analysis.
T tests were used to determine the statistical significance of differences observed in chromatin immunoprecipitation (ChIP)-quantitative polymerase chain reaction (qPCR), quantitative reverse transcription polymerase chain reaction (qRT-PCR), and ELISA experiments. T tests with Welch's correction when appropriate were used in the TCGA RNAseq data analysis. One-way analysis of variance (ANOVA) with Bonferroni's multiple comparison test was used in the MECA-32þ area analysis. HUVEC sprouting assay was analyzed using one-way ANOVA with Tukey's-Cramer post-test. P values of less than .05 were considered statistically significant. All statistical tests were two-sided.
All calculations were performed using SPSS 22 (IBM, Armonk, NY), Prism 5 (GraphPad, La Jolla, CA), R Survival Package, and JMP (SAS Institute, Cary NC).
Additional methods for mutation modeling, immunoprecipitation, microarray expression profiling, MAX and MYC genic occupancy, TCGA RNA-seq analysis, qRT-PCR, Sanger sequencing, TA cloning, and in vitro cell-based assays are provided in the Supplementary Methods (available online).
Results
MAX Mutations in EEC and Associations With Clinicopathologic Features Including Outcome
MAX was sequenced in 509 primary EECs (18, 22, 23) . The overall mutation rate was 4.3% (22 tumors with mutations). The p.His28Arg mutation was observed in 12 tumors, along with nine additional somatic variants in 11 tumors ( Figure 1A ). The hotspot p.His28Arg mutation was also observed by TCGA ( Figure 1A ) (4) . Variant allele fractions (VAFs) were consistent with full clonality (Supplementary Table 2 , available online). cDNA analysis for primary tumors showed expression of both wild-type (WT) and mutant alleles (corresponding to p.His28Arg), and immunoblot analysis showed comparable levels of MAX expression in wild-type and mutant tumors (data not shown). One tumor (specimen 2219) had two somatic mutations, p.His28Arg and the known cancer susceptibility allele p.Arg75*, which occurred in trans (Supplementary Figure 1 , available online) (13) . Two tumors (specimens 1122 and 1913) had apparent gain or loss of the MAX locus, as evidenced by single nucleotide polymorphism VAFs (Supplementary Table 2 , available online).
Patients with MAX-mutant tumors had reduced recurrencefree survival (RFS; HR ¼ 4.00, 95% CI ¼ 1.15 to 13.91, P ¼ .03) ( Figure 1B) . Mutation was statistically significantly associated with microsatellite instability, tumor stage, and patient BMI (Supplementary Table 3 , available online). MAX mutation status remained an independent predictor of reduced recurrence-free survival in a multivariable model that included age, grade, stage, and lymphovascular space invasion (HR ¼ 2.95, 95% CI ¼ 1.20 to 7.29, P ¼ .02), suggesting that MAX defects contribute to clinical aggressiveness ( Figure 1C ).
MAX p.His28Arg DNA Binding
Histidine 28 makes a critical contact with the E-box sequence (5'-CACGTG-3') by hydrogen bonding between NE2 and N7 and/ or O6 of Gua(3') (24) . Based on in silico prediction, the His28Arg substitution likely increases affinity for Gua(3') due to reduced bond length and/or bidentate interaction ( Figure 2A ). We therefore assessed DNA binding by EMSAs with IVT proteins. As MAX short isoform homodimers bind E-boxes poorly, we assayed long isoform MAX WT and MAX H28R using a canonical two-E-box sequence from the NPM1 promoter (25, 26) . Figure 2 , B and C), the observed results were not due to differences in MAX protein quantity. EMSA findings were similar using a previously studied four-E-box oligonucleotide from the CDK4 promoter (Supplementary Figure 2D) (27) . Single E-box oligonucleotides, however, showed no differences between MAX H28R and MAX WT , suggesting that multimeric MAX complexes could account for the differences seen with four-and two-E-box oligonucleotides (data not shown). MAX short isoform homodimers bound E-boxes poorly (Supplementary Figure  2E :DNA interaction, we performed ChIP-qPCR using AN3CA cells stably expressing flagtagged MAX H28R or MAX WT at levels comparable with endogenous MAX (Supplementary Figure 3 , available online). We assessed binding to E-boxes in the MAX/MYC target genes NPM1, CDK4, and CAD, and control regions in CTCF and KLHL13 (25, 27, 28) . MAX H28R showed statistically significantly enhanced affinity for the E-boxes in NPM1 and CDK4 compared with MAX WT (P < .001 and P ¼ .04, respectively) ( Figure 2E ). Together, these findings demonstrate that the p.His28Arg mutation alters DNA binding and could, therefore, alter gene expression.
MAX p.His28Arg Transcriptional Changes
TCGA RNA-seq data for the eight MAX-mutant and 156 MAX-WT EECs were used to explore differentially expressed genes (DEGs) ( Figure 2F ) (4). We identified 64 candidate DEGs with P values of less than .01 and greater than twofold expression change (Supplementary Figure 4A , available online). The majority (71%) bound MAX and/or MYC based on ENCODE ChIP-seq data, implying that MAX mutation might directly alter transcription (Supplementary Figure 4B , available online) (29) . Eight candidate DEGs were validated in our collection of EECs using qRT-PCR. Expression of GATM and SERPINB9 was statistically significantly different between mutant and WT tumors (P ¼ .02 and P ¼ .03, respectively) ( Figure 2F ), whereas expression of the other six candidates was not statistically significantly different (Supplementary Figure 4C, 
Vascular Phenotype of MAX H28R Xenograft Tumors
In vitro assays showed no differences in proliferation, colony formation, or wound healing for the stable MAX 
MAX H28R Pro-angiogenic Paracrine Signaling
To test the hypothesis that paracrine factors elaborated by MAX H28R -expressing cells contribute to the vascular phenotype in xenografts, we assessed HUVEC sprouting in vitro using a previously described microfluidic model (21) . We observed statistically significantly increased HUVEC sprouting with MAX H28R conditioned medium compared with MAX WT and EV (P ¼ .02
and P ¼ .005, respectively) ( Figure 4A ). As the expression array data (Supplementary Figure 5D, Figure 12 , available online). Taken to-
gether, these data demonstrate that MAX H28R in cancer cell lines promotes increased vascularity and that increased VEGFA secretion could contribute to the pro-angiogenic phenotype. 
Discussion
Determining how specific and presumably biologically relevant gene defects contribute to cancer phenotypes remains a challenge. Our functional characterization of the recurrent and ECspecific MAX p.His28Arg mutation provides important evidence that the mutation alters MAX function and contributes to a cancer-related phenotype, angiogenesis. -associated pro-angiogenesis. MAX-mediated increases in vascularity and VEGFA levels, both of which are associated with poor clinical outcome in EC patients, could in part explain selection for MAX mutation in EC (30) (31) (32) .
The mutation pattern of MAX that we observed strongly suggests a dominant or dominant-negative activity in EC ( Figure  1A) , consistent with our functional data. The paucity of stop and frameshift mutations and absence of second-hit mutations in EEC is in stark contrast to the loss-of-function abnormalities seen in neuroendocrine tumors, suggesting context-dependent roles for MAX (13) (14) (15) . Two amino acids in MAX appear to display substitutions that are specific to cancer type and that may have different functional consequences. Val9Met and Arg60Gln are observed in EECs, while Val9Leu and Arg60Trp are observed in pheochromocytomas (4, 14) . The two pheochromocytoma missense variants have been shown to be loss-of-function in terms of ability to repress MYC-driven expression of a reporter assay in rat PC12 cells null for MAX (33) . Although Val9Met and Arg60Gln are yet to be functionally tested in EC, the possibility exists that they are loss-of-function alleles, similar to the corresponding pheochromocytoma variants. However, the effect of these variants must be experimentally determined in additional systems given the complexity of MAX's transcription regulatory function.
There are several examples of context-dependent roles for cancer genes. FGFR2 is an oncogene in EC but acts as a tumor suppressor in melanoma (34, 35) . Loss-and gain-of-function defects occur in TP53; tumors that have an inherited loss-offunction mutation and a second somatic mutation point to p53's role as a tumor suppressor, but oncogenic missense changes that alter signaling cascades and chromatin modification also drive cancer in some instances (36) (37) (38) (39) . Most TP53 mutations abrogate p53's tumor suppressive function, acting either as cellular recessives or dominant-negatives (38) . Gain-offunction TP53 missense mutations in the DNA binding domain cause loss of wild-type p53 tumor suppressive function, alter genomic binding, and confer novel oncogenic activity (36) (37) (38) (39) . MAX defects may parallel the complex nature of TP53 mutations. Clear loss-of-function deletion and nonsense alleles exist for MAX, in addition to potentially more biologically complex missense mutations involving the DNA binding domain. Some mutations could be tissue-dependent loss-of-function alleles for certain activities, while at the same time conferring novel oncogenic properties.
Our finding that a recurrent cancer-specific mutation in MAX acts in a dominant manner is not unexpected. An endogenous truncated MAX protein called dMAX is a naturally occurring example of a dominant-negative MAX. dMAX can dimerize with MYC and MXD members but cannot associate with DNA, and it has been associated with increased aerobic metabolism (40) (41) (42) . MAX and MAX-like-protein X (MLX) are known to regulate transcriptional networks essential to tumor cell metabolism/nutrient availability, and it is possible that the increased vascularity seen in xenografts expressing MAX H28R is part of a central theme of MAX's important role in coordination of nutrient availability (43) . Further, the effect of the p.His28Arg mutation in DNA binding is likely to influence activities of many MAX-interacting proteins, not just its canonical partner MYC. This study is limited by characterization of a single hotspot mutation in the MAX gene. Further efforts will be required to determine whether the other observed MAX mutations alter DNA binding and/or increase angiogenesis. Although our study found that MAX mutation in EC patients was associated with poor outcome, analysis of additional cohorts will be required to validate the prognostic significance.
Our results link the MAX p.His28Arg mutation and tumor angiogenesis. The global effect on transcriptional profiles observed in cells expressing MAX H28R also implies there are additional gene expression changes that could contribute to biologic aggressiveness in EEC. Taken together, the findings from our mutation and functionalization studies implicate mutant MAX as a driver of aggressive EEC.
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